|
1.
|
Bruix J and Llovet JM: Major achievements
in hepatocellular carcinoma. Lancet. 373:614–616. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Shah SA, Greig PD, Gallinger S, et al:
Factors associated with early recurrence after resection for
hepatocellular carcinoma and outcomes. J Am Coll Surg. 202:275–283.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Lee EH, Kao WWY and Schwarz RI: Cell
density regulates prolyl 4-hydroxylase activity independent of mRNA
levels. Matrix Biol. 19:779–782. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Gupta S, Kobayashi S, Phongkitkarun S,
Broemeling LD and Kan Z: Effect of transcatheter hepatic arterial
embolisation on angiogenesis in an animal model. Invest Radiol.
41:516–521. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Doffoel M, Bonnetain F, Bouche O, et al:
Multicentre randomised phase III trial comparing tamoxifen alone or
with transarterial lipiodol chemoembolisation for unresectable
hepatocellular carcinoma in cirrhotic patients (Fédération
Francophone de Cancérologie Digestive 9402). Eur J Cancer.
44:528–538. 2008.
|
|
6.
|
Kudo M, Imanaka K, Chida N, et al: Phase
III study of sorafenib after transarterial chemoembolisation in
Japanese and Korean patients with unresectable hepatocellular
carcinoma. Eur J Cancer. 47:2117–2127. 2011. View Article : Google Scholar
|
|
7.
|
Britten CD, Gomes AS, Wainberg ZA, et al:
Transarterial chemoembolization plus or minus intravenous
bevacizumab in the treatment of hepatocellular cancer: a pilot
study. BMC Cancer. 12:162012. View Article : Google Scholar
|
|
8.
|
Breinig M, Schirmacher P and Kern MA:
Cyclooxygenase-2 (COX-2)-a therapeutic target in liver cancer? Curr
Pharm Design. 13:3305–3315. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Wu T: Cyclooxygenase-2 in hepatocellular
carcinoma. Cancer Treat Rev. 32:28–44. 2006. View Article : Google Scholar
|
|
10.
|
Zhao QT, Yue SQ, Cui Z, et al: Potential
involvement of the cyclooxygenase-2 pathway in hepatocellular
carcinoma-associated angiogenesis. Life Sci. 80:484–492. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Cheng AS, Chan HL, To KF, et al:
Cyclooxygenase-2 pathway correlates with vascular endothelial
growth factor expression and tumor angiogenesis in hepatitis B
virus-associated hepatocellular carcinoma. Int J Oncol. 24:853–860.
2004.
|
|
12.
|
Reubi JC, Zimmermann A, Jonas S, et al:
Regulatory peptide receptors in human hepatocellular carcinomas.
Gut. 45:766–774. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Xie Y, Chen S, Wang C and Tang C: SOM230
combined with celecoxib prolongs survival in nude mice with HepG-2
xenografts. Cancer Biol Ther. 12:86–92. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Tong H, Li X, Zhang CL, et al:
Transcatheter arterial embolization followed by octreotide and
celecoxib synergistically prolongs survival of rabbits with hepatic
VX2 allografts. J Dig Dis. Oct 5–2012.(Epub ahead of print).
|
|
15.
|
Wu TH, Yu MC, Chen TC, et al:
Encapsulation is a significant prognostic factor for better outcome
in large hepatocellular carcinoma. J Surg Oncol. 105:85–90. 2012.
View Article : Google Scholar
|
|
16.
|
Emile JF, Lemoine A, Azoulay D, Debuire B,
Bismuth H and Reynes M: Histological, genomic and clinical
heterogeneity of clear cell hepatocellular carcinoma.
Histopathology. 38:225–231. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Kashala LO, Conne B, Kalengayi MM, et al:
Histopathologic features of hepatocellular carcinoma in Zaire.
Cancer. 65:130–134. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Lai CL, Wu PC, Lam KC and Todd D:
Histologic prognostic indicators in hepatocellular carcinoma.
Cancer. 44:1677–1683. 1979. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Adamek HE, Spiethoff A, Kaumann V, et al:
Primary clear cell carcinoma of noncirrhotic liver:
immunohistochemical discrimination of hepatocellular and
cholangiocellular origin. Dig Dis Sci. 43:33–38. 1998. View Article : Google Scholar
|
|
20.
|
Murakata LA, Ishak KG and Nzeako UC: Clear
cell carcinoma of the liver: a comparative immunohistochemical
study with renal clear cell carcinoma. Mod Pathol. 13:874–881.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Liu Z, Ma W, Li H and Li Q:
Clinicopathological and prognostic features of primary clear cell
carcinoma of the liver. Hepatol Res. 38:291–299. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Iguchi T, Aishima S, Sanefuji K, et al:
Both fibrous capsule formation and extracapsular penetration are
powerful predictors of poor survival in human hepatocellular
carcinoma: a histological assessment of 365 patients in Japan. Ann
Surg Oncol. 16:2539–2546. 2009. View Article : Google Scholar
|
|
23.
|
Tanaka T, Yamanaka N, Oriyama T, Furukawa
K and Okamoto E: Factors regulating tumor pressure in
hepatocellular carcinoma and implications for tumor spread.
Hepatology. 26:283–287. 1997. View Article : Google Scholar : PubMed/NCBI
|
